iSelect Fund
  • Portfolio
  • Team
    • Team
    • Selection Committee
    • Portfolio Company CEOs
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Content
    • Blog
    • Videos
    • Agrifood Conversations
    • FAQ
  • Contact
    • Log In
    • Register
    • My iSelect
Select Page

Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors

Read more

University of Oklahoma Biomedical Engineering Professor Conducts Study to Develop Booster with Potential to Improve Eventual COVID-19 Vaccine

Read more

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors

Read more
2 Companies That Are Working to Cure Cancer Right Now

2 Companies That Are Working to Cure Cancer Right Now

In 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people died as a result of the disease, according to the National Cancer Institute. These numbers are staggering. The challenge for clinicians and researchers is... Read more

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors

Read more

CLS’ PRODUCTS AND METHOD ARE PLANNED TO BE USED IN A CLINICAL TRIAL, CARRIED OUT BY IMMUNOPHOTONICS, REGARDING EVALUATION OF NEW DRUG

Read more
« Older Entries

Related Posts

  • Sugar
    Bonumose: Creating Healthy, Affordable Sugars From Agriculture Waste Products
  • Immunophotonics
    Immunophotonics, SAKK Move Forward with Research Collaboration
  • Obesity Treatment
    Gila Therapeutics Completes Phase I Clinical Trial
  • Neuros Medical Nerve Block Technology
    iSelect Portfolio: Neuros Medical Closes $20 Million Funding Round
  • turf management solution
    Holganix for Property Managers: Stronger Turf, Better Profits

Our Networks

Food & Agriculture
Healthcare

(314) 219-8688

1401 S. Brentwood Blvd.
Suite 300
St. Louis, MO 63144

Crunchbase   Medium   Twitter   LinkedIn   Facebook   YouTube

Investments in private offerings are speculative, illiquid and involve a high degree of risk. It is not unusual for an investor in a private offering to lose the entire amount of the investment. Investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results. Securities are offered through North Capital Private Securities, member FINRA/SIPC. All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in futures or other investments. North Capital Inc. is a Registered Investment Advisor and Commodities Trading Advisor. North Capital Private Securities Corporation is a registered broker dealer, member FINRA | SIPC.

The relationship between North Capital Investment Technology, North Capital Inc., and North Capital Private Securities Corporation is described in our Disclosure Documents and Code of Ethics. Check the background of this firm on FINRA's BrokerCheck © 1999-2020. All Rights Reserved. Submit a Complaint

©2020 iSelect Fund | Your use of this website signifies that you accept iSelect’s website terms and conditions of use and privacy policy.